Compare TNC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNC | EVO |
|---|---|---|
| Founded | 1870 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | TNC | EVO |
|---|---|---|
| Price | $75.31 | $3.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $113.50 | $7.00 |
| AVG Volume (30 Days) | 152.8K | ★ 259.6K |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.91 | N/A |
| Revenue | ★ $1,240,800,000.00 | $887,396,457.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.63 | $8.52 |
| P/E Ratio | $25.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $67.32 | $2.84 |
| 52 Week High | $90.44 | $5.10 |
| Indicator | TNC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 50.69 |
| Support Level | $73.77 | $2.87 |
| Resistance Level | $75.90 | $3.05 |
| Average True Range (ATR) | 1.70 | 0.10 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 47.83 | 72.97 |
Tennant Co is a manufacturer of floor cleaning equipment, wood flooring, and wood products. It operates in four geographic business units including North America; Latin America; Europe, Middle East, Africa; and Asia Pacific. The company offers products and solutions consisting of mechanized cleaning equipment, detergent-free, and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, specialty surface coatings, and business solutions such as financing, rental and leasing programs, and machine-to-machine asset management solutions.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.